Melanie De Almeida, Author at Labiotech.eu

About

Former journalist intern. Melanie has studied in Germany and Denmark and did an internship at Novo Nordisk, where she had a glimpse to the workings of pharma. She is now a Ph.D. student at the IMP in Vienna.

Articles by Melanie De Almeida

More News! 4 Apr 2017

SynBioBeta Launches Venture Fund for Synthetic Biology Startups

US-based venture capital fund Data Collective has announced that it is partnering with SynBioBeta to launch a new synthetic biology venture fund. Data Collective will join forces with SynBioBeta founder John Cumbers to launch the DCVC SynBioBeta fund, a pre-seed and seed VC fund to invest in synthetic biology startups. John Cumbers, an expert on […]

April 4, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 3 Apr 2017

First Treatment for Severe Premenstrual Syndrome Clears Phase II

Swedish Asarina Pharma has announced positive results of a Phase IIa study for the treatment of Premenstrual Dysphoric Disorder (PMDD). With only a single product candidate in its pipeline, Asarina Pharma is focusing on the development of the first potential therapy for the treatment of PMDD, a severe and disabling form of premenstrual syndrome that affects about 5% of […]

April 3, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 30 Mar 2017

New Clues on How the Immune System Weakens with Age

By analyzing the responses of individual immune cells, a new study in Science provides new insights into the decline of the immune system with age. In a collaborative effort, researchers from the European Bioinformatics Institute (EMBL-EBI), University of Cambridge, the Wellcome Trust Sanger Institute and the Cancer Research UK–Cambridge Institute (CRUK-CI) have shed light on a […]

March 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […]

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

Regeneron Sanofi dupilumab Atopic Dermatitis

News and Trends 29 Mar 2017

Get Ready for One of the Biggest New Drug Approvals of the Year

After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With three placebo-controlled clinical trials enrolling a total of 2119 adult participants, Sanofi and its partner Regeneron were able to convince the FDA of their new biological for the treatment of atopic dermatitis. The product of this expansive effort comes […]

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

Lysogene gene therapy Sanfillipo A obs study

News and Trends 29 Mar 2017

French Gene Therapy Biotech Gets Ready for Phase II/III

Lysogene has crunched the numbers on its observational study for Sanfillipo A – now the company can move into the final phase for its Sanfilippo A therapy. Lysogene is a French biotech specializing in gene therapy of rare CNS diseases. Its lead asset is a gene therapy for the treatment of the rare genetic disorder […]

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

European Patent Office CRISPR Decision 1

News and Trends 28 Mar 2017

Europe Turns the Tables in the CRISPR Patent Battle

ERS Genomics has announced that the EPO intends to grant a patent with broad claims covering the use of CRISPR to Emmanuelle Charpentier. ERS Genomics has announced that the European Patent Office (EPO) will grant its founder, Emmanuelle Charpentier as well as the University of Vienna and University of California, Berkeley, a patent covering the broad use of CRISPR-Cas9 […]

March 28, 2017 - 3 minutesmins - By Melanie De Almeida

Infant Bacterial Therapeutics Biotech of the Week

Startup Scout 24 Mar 2017

This Swedish Biotech Uses Bacteria to Treat Diseases in Infants

This week’s biotech brought us to Scandinavia. Based in Sweden’s capital, Stockholm, Infant Bacterial Therapeutics aims to treat rare diseases affecting newborns by targeting the infant microbiome. Mission: Infant Bacterial Therapeutics (IBT) aims to treat rare diseases affecting infants for which there is currently no treatment available. The company makes use of live bacterial therapeutics, which modulate inflammatory […]

March 24, 2017 - 2 minutesmins - By Melanie De Almeida

Research Biosensor Chip Bacterial Infections 1

News and Trends 24 Mar 2017

New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection

Scientists from Israel have piloted a new silicon biosensor chip that can rapidly identify the best antibiotics for treating a bacterial infection. Antibiotic resistance makes up one of the major health challenges of the 21st century. Some of the major causes of the increasing numbers of resistant bacterial strains are overuse of antibiotics and mistreatment of infections. […]

March 24, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Mar 2017

A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa

An innovative rotavirus vaccine, BRV-PV, which does not require refrigeration, has passed Phase III trials in children living in sub-Saharan Africa. The Research and Epidemiology branch of the humanitarian organization Doctors without Borders (MSF), Epicentre, has published the results of its recent Phase III trial for a new oral vaccine against rotavirus infection. The vaccine, […]

March 23, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

eppendorf bioflo120 sponsored e1490947196269

News and Trends 23 Mar 2017

Speed up R&D? Eppendorf is Offering a new Solution!

With their latest bioreactor system, BioFlo 120, Eppendorf is aiming to make bioprocesses more flexible and straightforward. Apart from brewing beer, bioprocesses play a major role in the biotech industry. Ever since the breakthrough of genetic engineering technologies in the end of the last century, we have started to exploit microorganisms or mammalian cells as […]

March 23, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Melanie De Almeida

About

Articles by Melanie De Almeida

SynBioBeta Launches Venture Fund for Synthetic Biology Startups

First Treatment for Severe Premenstrual Syndrome Clears Phase II

New Clues on How the Immune System Weakens with Age

Merck Outsources the Development of its Nanobody for Psoriasis

Get Ready for One of the Biggest New Drug Approvals of the Year

French Gene Therapy Biotech Gets Ready for Phase II/III

Europe Turns the Tables in the CRISPR Patent Battle

This Swedish Biotech Uses Bacteria to Treat Diseases in Infants

New Biochips Quickly Identify the Best Antibiotic for each Bacterial Infection

A Cheaper Heat-Stable Vaccine Could Prevent Child Deaths in Africa

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Speed up R&D? Eppendorf is Offering a new Solution!

Subscribe to our newsletter to get the latest biotech news!